Abeona Therapeutics: Despite Some Competitive Pressure, This Looks Undervalued
Portfolio Pulse from
Abeona Therapeutics Inc. is advancing its lead program, pz-cel, an autologous gene therapy for RDEB, which has shown promising results in clinical trials. Despite receiving a CRL from the FDA, Abeona has resubmitted its BLA, with a new PDUFA date set for April 29, 2025. The stock is considered undervalued, with potential for significant gains if pz-cel is approved, supported by strong cash reserves and a valuable PRV.
January 24, 2025 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Abeona Therapeutics' lead program, pz-cel, is progressing despite FDA challenges. The resubmission of its BLA and a new PDUFA date in 2025 could lead to significant stock gains if approved. The company is financially strong with cash reserves and a PRV.
Abeona's pz-cel has shown positive clinical results, and the resubmission of its BLA indicates progress towards potential approval. The stock is currently undervalued, suggesting room for price appreciation if the therapy is approved. The company's strong financial position further supports its potential.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100